Immupharma Share Discussion Threads

[borromini1] 13/9/2018 21:40

An immediate brilliant move by IMM would be to use about £1m of cash for an immediate share buy back. If they average 14p per share they will have released many pessimistic share holders of their agony and have effectively bought back the entire issue from the last fund raise at a profit of £9m. Long term holders will love this reversal of dilution. Everyone wins, from their own blinkered prospective.

[colsmith] 13/9/2018 17:40

Guys, looking at the share price action and seeing conspiracy somewhere I wonder; after all the drop from 20p seems odd as really nothing has changed apart from an update that didn't give any practical view of the future - I mean early 2019 is where it will be more clear if there is a future unless something pops out of the woodwork so to speak. So is the share price due:

- a means to churn the price and generate cash - the sort of way the market operates; I mean all is fair in love and war and the financial market I guess;

- an entity with an interest in whatever IMM in the pharma market have, or the entity believes the company has, are involved in some way in in moving the price towards very little above zero or whatever price the entity believes will cause some market action.

In a sense there's nothing odd about the way the share price has moved as other companies are hit in a similar way when there's no optimistic view following a poor report.

Surely apart from the share price action there's really nothing to say - we just don't know much and opinion on the future of this company is just that- one can't disagree with an opinion but neither can one accept it.

[obiterdicta] 13/9/2018 12:43

But according to The Merlion and DannyBoy they have a cash pile and clinical assets like Nucant and Ureka.

Problem is that the cash pile is depleting month on month and the clinical assets have limited commercial value as those assets needs cash to progress through clinical trials to commercialisation..



OD

[nobbygnome] 13/9/2018 12:34

Hallelujah. Someone talking some sense on this thread at last!

[costax1654x] 13/9/2018 10:27

Sbtx +8% today...get in before RNS,big rerate expected

[ken chung] 13/9/2018 08:15

Amazing to watch the mm's raise the price this morning, demonstrating how easy it is to entice lemmings into buying absolute worthless dross.Anyone want to chase the price of dross up today?

[oldvic] 13/9/2018 08:04

LONG TIME JONNY AUCTION THIS MORNING

[ken chung] 13/9/2018 00:47

Lemmings and muppets only now.

[the_merlion] 12/9/2018 17:22

LOL.

buywell keep watching the charts, let me know what they say overnight once that blue finish is put into the statistics.

[ukdannyboy] 12/9/2018 17:08

Except it’s gone into a Managed Access Program and they have not ruled out Seeking FDA approval. If you read the info when it failed it makes this quite clear. They also highlight why the placebo and their drug were only a 10% difference was because the placebo weren’t just receiving a placebo they were receiving ongoing steroid treatment. FDA would be aware of this. They also have other drugs in the pipeline and own a subsidiary etc. You say DYOR but apparently you’ve done none lol...

[buywell3] 12/9/2018 15:26

buywell318 May '18 - 14:43 - 31314 of 33503 Edit
0 2 1
If Lupuzor is the only thing this company has, then the latest Phase 3 trials results suggest that only the cash pile and hard assets plus staff have any worth IMO

That is to say , it looks chartwise as if this has further to drop

dyor

[the_merlion] 12/9/2018 12:31

UKDannyboy, Better clean up those figures, you know obi will throw one of those famous girly hissy fits on here if we don't.



''The January 2018 placing gross proceeds of £10 million
added to the Group’s cash and cash equivalent position of
£2.7 million ''

So we had £12.7m in January 2018. The admin costs are low at £1.5m a year. There are still three months to year end, but lets not penny pinch, and call it £1.5m spent to date.

That leaves £11.2m in the bank right now. Well deduct the £2m investment when its done, but that will sit on the books as a asset anyway. But for right now we are cash rich at £11.2m.

Market cap is now £18m, so its valuing the rest of the company, which includes Lupuzor™ Nucant program and Ureka at £6.8m only. All I can say to that is LOL. Thats is like saying hey come over and buy our company today at £6.8m - I dont think so.





Pipeline Overview

LupuzorTM / Forigerimod / P140 in auto
immune indications
Lupuzor™, is also known by its chemical name
‘Forigerimod’ or P140. ImmuPharma in conjunction with
the CNRS are exploring opportunities on expanding
the P140 auto immune pipeline, as demonstrated by
Lupuzor™'s strong efficacy and safety profile and by its
mechanism of action.
Certain auto immune indications, outside of lupus, have
the potential for Orphan Drug designation. Further
assessment continues with the objective of further
indications moving into the clinic in due course.
Nucant Program


Our cancer Nucant program, IPP-204106, is focused on
combination therapy approaches. Two Phase I/IIa trials
were performed (focused on safety and dose-range
finding). ImmuPharma is now reviewing a number of
options to further progress this program. A grant was
awarded by the EU to different EU partners (€7 million
total with €430k awarded to ImmuPharma) to develop the
Nucants in combination with cytotoxic drugs linked to a
solid support. The molecule has also shown promising
results in age-related macular degeneration models.
Peptide Platform


ImmuPharma’s subsidiary ‘Ureka’ has also initiated
the development of a novel and innovative peptide
technology platform through the collaboration with CNRS,
thereby gaining access to pioneering research centred
on novel peptide drugs at the University of Bordeaux
and the Institut Européen de Chimie et Biologie (IECB).
Jointly, ImmuPharma and CNRS have filed a series of new
co-owned patents controlling this breakthrough peptide
technology. The first therapeutic area being targeted is
diabetes with glucagon-like peptide -1 agonists, a class
of drugs for the treatment of diabetes, as well as initiating
the development of novel peptides as glucagon agonists -
one of the novel approaches to treat Type I and Type II
diabetes. These peptides could also have a beneficial
effect in the treatment of NASH (Non-Alcoholic Steato
Hepatitis) for which very few treatment options exist.

[ukdannyboy] 12/9/2018 11:46

Market has realised how undervalued this is at an 18m market cap with 12m cash in the bank! Should be 20-25p

[aussieb3] 12/9/2018 11:33

That why it's going up big buy 350,000

[miahkaysor] 12/9/2018 11:32

Takeover target?????

[miahkaysor] 12/9/2018 11:22

I am a buyer!

nai.

[ken chung] 12/9/2018 09:16

Why don't all board members each have their salaries cut to £15,000 pa instead of continuing to draw six figure sums? Afterall lupuzor failed miserably.

[ken chung] 12/9/2018 09:00

Get out before its suspended at 5p.

[the_merlion] 12/9/2018 08:32

No directors are selling stock and have no intention to do so

We will be conducting interviews over the near term

We also hope to give further updates to the market in the near term

Many thanks
Lisa

Lisa Baderoon
Head of Investor Relations
ImmuPharma PLC

[nobbygnome] 11/9/2018 20:55

That's great; I certainly don't feel any more informed having read yours either. At least my post is factual....